Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

What is the cutest thing you have ever seen?

Chances are it involves a baby, a puppy or another adorable animal. And chances are it is forever imprinted on your mind. But what exactly is this powerful attractive force and how is it expressed in the brain?

Together with our colleagues Marc Bornstein from the National Institute of Child Health and Human Development and Catherine Alexander from the University of Oxford, we have reviewed the existing research on the topic and discovered that cuteness is more than something purely visual. It works by involving all the senses and strongly attracting our attention by sparking rapid brain activity. In fact, cuteness may be one of the strongest forces that shape our behaviour – potentially making us more compassionate.

Read the full article on The Conversation website, written by Morten L. Kringelbach, Alan Stein and Eloise Stark, Department of Psychiatry.

Oxford is a subscribing member of The Conversation. Find out how you can write for The Conversation.

Similar stories

Largest ever global study of tuberculosis identifies genetic causes of drug resistance

Using cutting-edge genomic sequencing techniques, researchers at the University of Oxford have identified almost all the genomic variation that gives people resistance to 13 of the most common tuberculosis (TB) drug treatments.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

No benefit of convalescent plasma for critically ill COVID-19 patients

A large study of over 2000 COVID-19 patients has found that giving critically ill patients blood plasma from recovered COVID-19 patients did not significantly reduce deaths, or the need for intensive care support such as being put on a ventilator machine.

Increased infectiousness of coronavirus variants explained

Researchers from the Universities of Oxford and Dundee have made a discovery that helps explain why variations in the virus causes COVID-19 to spread so rapidly.

RECOVERY Trial paper wins BMJ’s 2021 UK Research Paper of the Year Award

For the second year in a row, The British Medical Journal have selected a publication co-authored by Oxford University researchers for their prestigious UK Research Paper of the Year Award. This award recognises original UK research that has the potential to contribute significantly to improving health and healthcare.